← Back to Search

Progestogen

Progesterone for Pre-eclampsia (PROGRESS Trial)

Phase 2
Recruiting
Led By Babbette LaMarca, PhD
Research Sponsored by Babbette Lamarca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline until delivery
Awards & highlights

PROGRESS Trial Summary

This trial will test if 17 OHPC given to preeclamptic mothers before 34 weeks improves mother and baby outcomes.

Who is the study for?
This trial is for pregnant patients at UMMC with preterm preeclampsia between 23 and 34 weeks of gestation, who can consent to study procedures. It excludes those with conditions like PPROM after 34 weeks, low platelets, liver issues, severe fetal growth restriction, eclampsia, or any maternal/fetal condition requiring urgent delivery.Check my eligibility
What is being tested?
The study investigates whether the hormone medication called 17-hydroxyprogesterone caproate (17 OHPC) can improve outcomes for mothers and babies when preeclampsia occurs before the baby is full-term.See study design
What are the potential side effects?
While specific side effects are not listed here, hormones like 17 OHPC could potentially cause injection site reactions, mood changes, headaches or increase the risk of certain pregnancy complications.

PROGRESS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~delivery
This trial's timeline: 3 weeks for screening, Varies for treatment, and delivery for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Improvement of maternal and perinatal outcomes
Other outcome measures
Assessment of APGAR score
Assessment of Acute Kidney Injury
Assessment of Biomarkers
+11 more

PROGRESS Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ExperimentalExperimental Treatment1 Intervention
To determine if the addition of 17 OHPC to the management of Severe PE diagnosed prior to 34 weeks gestation improves maternal and perinatal outcomes.
Group II: ControlActive Control1 Intervention
To determine how close the molecular markers are with 17 OHPC added to the management protocol.

Find a Location

Who is running the clinical trial?

Babbette LamarcaLead Sponsor
Babbette LaMarca, PhDPrincipal InvestigatorUniversity of Missisippi Medical Center

Media Library

17 OHPC (Progestogen) Clinical Trial Eligibility Overview. Trial Name: NCT02989025 — Phase 2
Pregnancy Research Study Groups: Experimental, Control
Pregnancy Clinical Trial 2023: 17 OHPC Highlights & Side Effects. Trial Name: NCT02989025 — Phase 2
17 OHPC (Progestogen) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02989025 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this study enrolling seniors aged 55 and above?

"Based on the research criteria, only people between 18 and 45 years old are eligible to partake in this medical study."

Answered by AI

How is 17 OHPC typically employed therapeutically?

"17 OHPC is a viable solution for the prevention or management of uterine haemorrhage, preterm birth, and premature deliveries."

Answered by AI

What type of participants is most suitable for this medical research?

"To qualify for this medical experiment, a patient should have pre-eclampsia and be between 18 to 45 years old. Approximately 60 people are being sought after."

Answered by AI

Is 17 OHPC detrimental to human health?

"While clinical trials have indicated that 17 OHPC is relatively safe, the lack of data supporting efficacy warrants a score of 2."

Answered by AI

How many participants are currently partaking in this research?

"Indeed, the program is actively enrolling patients as indicated on clinicaltrials.gov. This project was initially published on May 22nd 2017 and most recently amended on January 5th 2022; it seeks to recruit 60 individuals from a single site."

Answered by AI

Are there presently any openings for study participants?

"According to information on clinicaltrials.gov, enrollment is currently open for this trial which was initially made available on May 22nd 2017 and recently modified on January 5th 2022."

Answered by AI

Are there other investigations that have focused on 17 OHPC?

"Currently, there are two active clinical trials involving 17 OHPC and neither of them is in Phase 3. These studies can be found in Jackson, Mississippi as well as one other location across the nation."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia
Babbette Lamarca 2017. "Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02989025.
All > Preeclampsia
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top